Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype.
Adult
Biomarkers, Tumor
/ genetics
Bone Neoplasms
/ genetics
DNA-Binding Proteins
/ genetics
Female
Gene Fusion
Gene Rearrangement
Genetic Predisposition to Disease
Humans
In Situ Hybridization, Fluorescence
Male
Myeloid Ecotropic Viral Integration Site 1 Protein
/ genetics
Nuclear Receptor Coactivator 2
/ genetics
Phenotype
RNA-Binding Protein EWS
/ genetics
RNA-Binding Protein FUS
/ genetics
Rhabdomyosarcoma
/ genetics
Sequence Analysis, RNA
Transcription Factors
/ genetics
Young Adult
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pubmed:
6
2
2019
medline:
20
2
2020
entrez:
6
2
2019
Statut:
ppublish
Résumé
Primary intraosseous rhabdomyosarcomas (RMSs) are extremely rare. Recently 2 studies reported 4 cases of primary intraosseous RMS with EWSR1/FUS-TFCP2 gene fusions, associated with somewhat conflicting histologic features, ranging from spindle to epithelioid. In this study we sought to further investigate the pathologic and molecular abnormalities of a larger group of intraosseous RMSs by a combined approach using targeted RNA sequencing analysis and fluorescence in situ hybridization (FISH). We identified 7 cases, 3 males and 4 females, all in young adults, age range 20 to 39 years (median, 27 y). Three cases involved the pelvis, 2 involved the femur and 1 each involved the maxilla and the skull. Molecular studies identified recurrent gene fusions in all 7 cases tested, including: a novel MEIS1-NCOA2 fusion in 2 cases, EWSR1-TFCP2 in 3 cases, and FUS-TFCP2 gene fusions in 1 case. One case showed a FUS gene rearrangement, without a TFCP2 gene abnormality by FISH. The MEIS1-NCOA2-positive cases were characterized by a more primitive and fascicular spindle cell appearance, while the EWSR1/FUS rearranged tumors had a hybrid spindle and epithelioid phenotype, with more abundant eosinophilic cytoplasm and mild nuclear pleomorphism. Immunohistochemically, all tumors were positive for desmin and myogenin (focal). In addition, 4 tumors with TFCP2-associated gene fusions also coexpressed ALK and cytokeratin. In conclusion, our results suggest a high incidence of gene fusions in primary RMSs of bone, with 2 molecular subsets emerging, defined by either MEIS1-NCOA2 or EWSR1/FUS-TFCP2 fusions, showing distinct morphology and immunophenotype. Additional studies with larger numbers of cases and longer follow-up data are required to definitively evaluate the biological behavior of these tumors and to establish their relationship to other spindle cell RMS genetic groups.
Identifiants
pubmed: 30720533
doi: 10.1097/PAS.0000000000001227
pmc: PMC6613942
mid: NIHMS1533010
doi:
Substances chimiques
Biomarkers, Tumor
0
DNA-Binding Proteins
0
EWSR1 protein, human
0
FUS protein, human
0
MEIS1 protein, human
0
Myeloid Ecotropic Viral Integration Site 1 Protein
0
NCOA2 protein, human
0
Nuclear Receptor Coactivator 2
0
RNA-Binding Protein EWS
0
RNA-Binding Protein FUS
0
TFCP2 protein, human
0
Transcription Factors
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
695-702Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA140146
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217694
Pays : United States
Références
Genes Chromosomes Cancer. 2010 Mar;49(3):224-36
pubmed: 19953635
Genes Chromosomes Cancer. 2012 May;51(5):510-20
pubmed: 22337624
Eur J Cancer. 2000 Dec;36(18):2368-74
pubmed: 11094311
Am J Surg Pathol. 2016 Feb;40(2):224-35
pubmed: 26501226
Pediatr Dev Pathol. 2009 Jul-Aug;12(4):275-83
pubmed: 18788887
Bioessays. 2017 May;39(5):
pubmed: 28322463
Oncotarget. 2015 Sep 22;6(28):26266-77
pubmed: 26313006
Eur J Cancer. 2007 Nov;43(17):2495-505
pubmed: 17949970
Hum Pathol. 2018 Jul;77:28-34
pubmed: 29559236
J Craniofac Surg. 2018 May;29(3):e221-e224
pubmed: 29283939
Oncotarget. 2016 Sep 13;7(37):58903-58914
pubmed: 27385213
Virchows Arch A Pathol Anat Histopathol. 1993;423(1):65-9
pubmed: 8212536
EBioMedicine. 2016 Jul;9:110-119
pubmed: 27333032
Ann Hematol. 2017 Apr;96(4):567-574
pubmed: 28054140
Genes Chromosomes Cancer. 2013 Jun;52(6):538-50
pubmed: 23463663
Histopathology. 2002 Nov;41(5):461-7
pubmed: 12405914
J Craniomaxillofac Surg. 2017 Jun;45(6):831-838
pubmed: 28431807
Gene. 2004 Dec 8;343(1):23-40
pubmed: 15563829
Oncotarget. 2016 Jan 19;7(3):2379-90
pubmed: 26506241
Oncol Rep. 2016 Nov;36(5):2455-2462
pubmed: 27633981
Genes Chromosomes Cancer. 2010 Dec;49(12):1114-24
pubmed: 20815032
Ann Otol Rhinol Laryngol Suppl. 1984 Jul-Aug;112:71-3
pubmed: 6431885
Am J Surg Pathol. 2018 Nov;42(11):1562-1570
pubmed: 30179902
J Oral Maxillofac Surg. 1987 May;45(5):441-3
pubmed: 3471927
J Pathol. 2018 May;245(1):29-40
pubmed: 29431183
J Exp Clin Cancer Res. 2011 Dec 20;30:112
pubmed: 22185299
Curr Opin Hematol. 2016 Jul;23(4):354-61
pubmed: 27258906
World J Clin Cases. 2017 Dec 16;5(12):440-445
pubmed: 29291204
Am J Surg Pathol. 1996 Feb;20(2):239-44
pubmed: 8554114
Histopathology. 2018 Sep;73(3):514-520
pubmed: 29758589
Genes Dev. 2007 Nov 1;21(21):2762-74
pubmed: 17942707
Arch Otorhinolaryngol. 1987;244(4):195-7
pubmed: 3689197
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8357-62
pubmed: 20404171
Curr Drug Targets. 2018;19(2):181-190
pubmed: 28745213
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4503-8
pubmed: 22396589
J Biol Chem. 1994 Apr 15;269(15):11663-71
pubmed: 8157699
Mol Cell Biol. 1994 Mar;14(3):1776-85
pubmed: 8114710
BMC Cancer. 2017 Mar 7;17(1):176
pubmed: 28270206
Genes Chromosomes Cancer. 2012 Feb;51(2):127-39
pubmed: 22034177